A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Phase of Trial: Phase III
Latest Information Update: 28 Dec 2017
At a glance
- Drugs Nintedanib (Primary)
- Indications Interstitial lung diseases
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 20 Mar 2017 According to a Boehringer Ingelheim media release, Kevin Flaherty is coordinating Principal Investigator of this trial.
- 20 Mar 2017 The first patient has been enrolled in this trial, as reported in a Boehringer Ingelheim media release.
- 26 Jan 2017 Status changed from not yet recruiting to recruiting.